AbbVie Seeks Approval of Upadacitinib for Ulcerative Colitis
The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.
Ulcerative Colitis
Corticosteroid Use Declines in Patients With IBD Over Past 20 Years
Investigators assessed trends in corticosteroid use in patients with IBD over a period of 20 years.
Upadacitinib Meets Endpoints in Ulcerative Colitis Maintenance Trial
A significantly greater proportion of patients treated with upadacitinib 15mg and 30mg achieved clinical remission at week 52 compared with those receiving placebo.
Zeposia Approved for Moderately to Severely Active Ulcerative Colitis
The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.
COVID-19 Vaccination of IBD Patients: Do Biologics Impact Serological Responses?
Patients with IBD were compared to control groups without IBD, which included 14 completely vaccinated healthcare workers and 29 vaccinated healthy volunteers.
Clinical Remission Reported With Mirikizumab in Ulcerative Colitis Trial
LUCENT-1 is a 12-week, double-blind, placebo-controlled induction study evaluating mirikizumab in over 1100 UC patients who had an inadequate response to, loss of response, or were intolerant to conventional or biologic therapy for UC.
Humira Approved for Pediatric Ulcerative Colitis
The pediatric approval was based on data from the multicenter, randomized, double-blind phase 3 ENVISION I study.
Upadacitinib Meets End Points in Ulcerative Colitis Trial
The U-ACCOMPLISH induction study evaluated the efficacy and safety of upadacitinib in 515 adults with moderate to severe ulcerative colitis.
Ozanimod Gets Priority Review for Ulcerative Colitis
The submission is supported by data from the True North trial that assessed ozanimod as an induction and maintenance therapy for adults with moderately to severely active UC who had an inadequate response to prior treatment.
De-Escalation and Discontinuation of Biologics in IBD: What to Consider
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
